The results suggest that the allicin treatment prevented systemic and lung endothelial dysfunction during PAH by preserving NO bioavailability, likely mediated by maintaining the eNOS in the coupled state (increasing synthesis or reducing degradation). The gene discussed is NOS3; the disease is pulmonary arterial hypertension.